These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Dopamine D2 receptors' effects on renal inflammation are mediated by regulation of PP2A function. Zhang Y; Jiang X; Qin C; Cuevas S; Jose PA; Armando I Am J Physiol Renal Physiol; 2016 Jan; 310(2):F128-34. PubMed ID: 26290374 [TBL] [Abstract][Full Text] [Related]
24. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908 [TBL] [Abstract][Full Text] [Related]
25. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. O'Brien WT; Harper AD; Jové F; Woodgett JR; Maretto S; Piccolo S; Klein PS J Neurosci; 2004 Jul; 24(30):6791-8. PubMed ID: 15282284 [TBL] [Abstract][Full Text] [Related]
26. Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling. Klewe IV; Nielsen SM; Tarpø L; Urizar E; Dipace C; Javitch JA; Gether U; Egebjerg J; Christensen KV Neuropharmacology; 2008 Jun; 54(8):1215-22. PubMed ID: 18455202 [TBL] [Abstract][Full Text] [Related]
27. Effects of the Ras homolog Rhes on Akt/protein kinase B and glycogen synthase kinase 3 phosphorylation in striatum. Harrison LM; Muller SH; Spano D Neuroscience; 2013 Apr; 236():21-30. PubMed ID: 23380502 [TBL] [Abstract][Full Text] [Related]
28. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease. Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399 [TBL] [Abstract][Full Text] [Related]
29. Antipsychotic-Like Efficacy of Dopamine D Sahlholm K; Gómez-Soler M; Valle-León M; López-Cano M; Taura JJ; Ciruela F; Fernández-Dueñas V Mol Neurobiol; 2018 Jun; 55(6):4952-4958. PubMed ID: 28779351 [TBL] [Abstract][Full Text] [Related]
30. Chronic administration of aripiprazole activates GSK3β-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats. Pan B; Huang XF; Deng C Sci Rep; 2016 Jul; 6():30040. PubMed ID: 27435909 [TBL] [Abstract][Full Text] [Related]
31. Differential effects of amisulpride and haloperidol on dopamine D2 receptor-mediated signaling in SH-SY5Y cells. Park SW; Seo MK; Cho HY; Lee JG; Lee BJ; Seol W; Kim YH Neuropharmacology; 2011 Sep; 61(4):761-9. PubMed ID: 21663752 [TBL] [Abstract][Full Text] [Related]
32. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. Etievant A; Bétry C; Arnt J; Haddjeri N Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663 [TBL] [Abstract][Full Text] [Related]
33. The role of beta-arrestin2 in shaping fMRI BOLD responses to dopaminergic stimulation. Sahlholm K; Ielacqua GD; Xu J; Jones LA; Schlegel F; Mach RH; Rudin M; Schroeter A Psychopharmacology (Berl); 2017 Jul; 234(13):2019-2030. PubMed ID: 28382543 [TBL] [Abstract][Full Text] [Related]
34. Glycogen-Synthase Kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Skurk C; Maatz H; Rocnik E; Bialik A; Force T; Walsh K Circ Res; 2005 Feb; 96(3):308-18. PubMed ID: 15662032 [TBL] [Abstract][Full Text] [Related]
35. Engineered D2R Variants Reveal the Balanced and Biased Contributions of G-Protein and β-Arrestin to Dopamine-Dependent Functions. Rose SJ; Pack TF; Peterson SM; Payne K; Borrelli E; Caron MG Neuropsychopharmacology; 2018 Apr; 43(5):1164-1173. PubMed ID: 29068002 [TBL] [Abstract][Full Text] [Related]
36. A dopamine D1 receptor-dependent β-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Urs NM; Daigle TL; Caron MG Neuropsychopharmacology; 2011 Feb; 36(3):551-8. PubMed ID: 20980993 [TBL] [Abstract][Full Text] [Related]
37. Functionally Biased D2R Antagonists: Targeting the β-Arrestin Pathway to Improve Antipsychotic Treatment. Weïwer M; Xu Q; Gale JP; Lewis M; Campbell AJ; Schroeder FA; Van de Bittner GC; Walk M; Amaya A; Su P; D Ordevic L; Sacher JR; Skepner A; Fei D; Dennehy K; Nguyen S; Faloon PW; Perez J; Cottrell JR; Liu F; Palmer M; Pan JQ; Hooker JM; Zhang YL; Scolnick E; Wagner FF; Holson EB ACS Chem Biol; 2018 Apr; 13(4):1038-1047. PubMed ID: 29485852 [TBL] [Abstract][Full Text] [Related]
38. Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Bersudsky Y; Shaldubina A; Kozlovsky N; Woodgett JR; Agam G; Belmaker RH Behav Pharmacol; 2008 May; 19(3):217-24. PubMed ID: 18469539 [TBL] [Abstract][Full Text] [Related]
39. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling. Sutton LP; Rushlow WJ Neuroscience; 2011 Dec; 199():116-24. PubMed ID: 22001305 [TBL] [Abstract][Full Text] [Related]
40. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Leite JV; Guimarães FS; Moreira FA Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]